PTPRJ

Across TCGA pan-cancer cohorts, PTPRJ RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of PTPRJ’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where PTPRJ RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PTPRJ is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

STAD, LIHC, and THCA are the cancer types where PTPRJ tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPRJ RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	II,III,IV	+1.279	<.001	8	view →
LIHC	Female	All	+0.923	<.001	8	view →
THCA	Male	All	−0.647	<.001	8	view →
UCEC	All	All	+0.702	.034	6	view →
KIRC	Male	II,III,IV	−0.555	<.001	6	view →
BRCA	All	All	+0.524	<.001	6	view →
CHOL	All	All	+1.266	.001	5	view →
KICH	All	All	+0.825	<.001	4	view →
LUSC	Male	All	−0.806	<.001	4	view →
COAD	Female	All	−0.634	.002	2	view →
PRAD	All	All	+0.530	<.001	2	view →
BLCA	Male	III,IV	+0.399	.039	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

PTPRJ–STAD

Open the STAD breakdown →